Biological Validation of Increased Schizophrenia Risk With NRG1, ERBB4, and AKT1 Epistasis via Functional Neuroimaging in Healthy Controls

Authors:
  • EREugenia Radulescu
    Eugenia Radulescu
  • ALAugustin Luna
    Augustin Luna
  • BKBhaskar Kolachana
    Bhaskar Kolachana
  • RVRadhakrishna Vakkalanka
    Radhakrishna Vakkalanka
  • DRDan Rujescu
    Dan Rujescu
  • IGIna Giegling
    Ina Giegling
  • RSRichard E. Straub
    Richard E. Straub
  • KMKate McGee
    Kate McGee
  • BGBert Gold
    Bert Gold
  • MDMichael Dean
    Michael Dean

Abstract
Neuregulin 1 (NRG1) is considered a schizophrenia candidate gene because of its chromosomal position within a linkage peak, direct evidence supporting genetic association with various polymorphisms,1-12 and its biological role in brain development and neural function mediated partially via the N -methyl-D-aspartate (NMDA)–glutamate pathway. Association has been confirmed at both the 5′ and 3′ ends,1-12 although null studies have appeared.13-20 One meta-analysis21 of the original risk-associated haplotype first identified in an Icelandic sample (HAPICE) revealed a small effect size (odds ratio [OR], 1.22) but strong statistical association (P value = 8.0 × 10−10), and another showed a significant, but weaker, association (P value = .036).22 However, these meta-analyses do not consider recently published genome-wide association study data that have provided less robust evidence. Although schizophrenia is thought to be a polygenic disorder, few studies of NRG1 epistasis have been conducted. There have been reports of interaction between HAPICE and its receptor ERBB4.23-25 However, none of these interactions were independently validated and recent data suggest that epistasis is likely the product of higher-order (ie, >2 single-nucleotide polymorphisms [SNPs]) interactions that these studies were not designed to detect.26

This publication has 56 references indexed in Scilit: